Peter Rothschild, President of BioGaia, summarises the first quarter of 2015 and answers questions regarding;

  • main reasons to strong results in first quarter,
  • the Brasilian market and its future,
  • agreement with Nestlé regarding development of new products,
  • the BioGaia subsidary IBT (Infant Bacterial Therapeutics) and its NEC-project,
  • and the new agreement in Mexico regarding sales of Oral Health tablets